RxDoctor Payments Data

Carlos Vidal, MD

Hematology & Oncology · Miami, FLNPI 1891783932

Payments from drug & device makers

$15,653in general payments, 2019–2025

Across 637 payments — averaging $24.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Bristol Myers Squibb$1K
  • Johnson & Johnson$1K
  • Pfizer$1K
  • Merck$1K
  • Novartis$728
  • plus $8K from 53 others

What the payments were for

  • Speaking & faculty fees$5003%
  • Food & beverage$14,46692%
  • Education$6874%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca79$2,113
Bristol Myers Squibb57$1,465
Johnson & Johnson(2 entities)50$1,294
Pfizer52$1,118
Merck48$1,117
Novartis33$728
E.r. Squibb & Sons, L.L.C.33$611
Incyte Corporation21$572
Verity Pharmaceuticals Inc.3$550
Daiichi Sankyo Inc.21$517
Bayer20$428
Lilly USA, LLC20$395
Takeda Pharmaceuticals U.S.A., Inc.15$393
Amgen15$297
Astellas Pharma US Inc9$246
AbbVie11$243
Seagen Inc.7$238
Regeneron Healthcare Solutions, Inc.8$235
Beigene USA, Inc.11$228
Array Biopharma Inc10$226
Gilead(2 entities)9$198
Sanofi7$193
EMD Serono, Inc.8$162
Eisai Inc.7$149
Ipsen Biopharmaceuticals, Inc3$124
GSK5$122
Sobi, Inc4$115
Mirati Therapeutics, Inc.5$109
Sun Pharmaceutical Industries Inc.5$108
Exelixis Inc.5$104
Pharmacosmos Therapeutics Inc.4$101
Genentech USA, Inc.4$97
Tempus AI, Inc4$92
Taiho Oncology, Inc.4$89
Myriad Genetic Laboratories, Inc.4$89
Amneal Pharmaceuticals LLC3$77
Caris MPI, Inc.3$62
Jazz Pharmaceuticals Inc.2$55
Rigel Pharmaceuticals, Inc.2$53
Stemline Therapeutics Inc.3$53
Iovance Biotherapeutics, Inc.2$47
Dendreon Pharmaceuticals LLC2$45
CTI Biopharma Corp.2$35
Pharmaand GmbH2$29
Servier Pharmaceuticals LLC1$28
Tesaro, Inc.1$28
Kyowa Kirin, Inc.1$27
Blue Earth Diagnostics1$26
Genmab U.S., Inc.1$26
Syndax Pharmaceuticals, Inc.1$25
Beone Medicines USA, Inc.1$24
Pharmacyclics LLC, An Abbvie Company1$22
Adaptive Biotechnologies Corporation1$21
Springworks Therapeutics, Inc.1$20
ADC Therapeutics America, Inc.1$18
Puma Biotechnology, Inc.1$17
Boehringer Ingelheim1$17
Deciphera Pharmaceuticals Inc.1$16
Tolmar, Inc.1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,653 in reported general payments places this provider in the 50th percentile of 694 hematology & oncology providers in Florida.

See all hematology & oncology providers in Florida

Medicare billing

Part B allowed, 2024
$321,257
Medicare patients
75
Services billed
30,343

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lenalidomide45$686,566
XtandiEnzalutamide29$413,823
RevlimidLenalidomide23$403,590
KeytrudaPembrolizumab25$289,997
IbrancePalbociclib14$247,255
KisqaliRibociclib Succinate12$199,536
MvasiBevacizumab-Awwb26$147,899
Lupron DepotLeuprolide Acetate14$43,942
Imatinib Mesylate12$27,930
ProcritEpoetin Alfa11$17,297
Ondansetron Hcl108$6,133
Anastrozole126$1,192
Hydroxyurea60$954
Anagrelide Hcl12$914
Dexamethasone69$898

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi$246$413,82329 claims
Bristol Myers SquibbRevlimid$1,465$403,59023 claims
MerckKeytruda$1,117$289,99725 claims
PfizerIbrance$1,118$247,25514 claims
NovartisKisqali$728$199,53612 claims
AmgenMvasi$297$147,89926 claims
AbbVieLupron Depot$243$43,94214 claims
Johnson & JohnsonProcrit$1,294$17,29711 claims
Lilly USA, LLCOlanzapine$395$15515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 694 hematology & oncology providers in Florida.

Other hematology & oncology in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →